The Methyltransferase METTL3 Negatively Regulates Nonalcoholic Steatohepatitis (NASH) Progression

Overview

Journal Nat Commun

Specialty Biology

Date 2021 Dec 11

PMID 34893641

Citations 36

Authors

Xinzhi Li

Bingchuan Yuan

Min Lu

Yuqin Wang

Na Ding

Chunhong Liu

Ming Gao

Zhicheng Yao

Shiyan Zhang

Yujun Zhao

Liwei Xie

Zheng Chen

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic steatohepatitis (NASH) is a key step in the progression of nonalcoholic fatty liver (NAFL) to cirrhosis. However, the molecular mechanisms of the NAFL-to-NASH transition are largely unknown. Here, we identify methyltransferase like 3 (METTL3) as a key negative regulator of NASH pathogenesis. Hepatocyte-specific deletion of Mettl3 drives NAFL-to-NASH progression by increasing CD36-mediated hepatic free fatty acid uptake and CCL2-induced inflammation, which is due to increased chromatin accessibility in the promoter region of Cd36 and Ccl2. Antibody blockade of CD36 and CCL2 ameliorates NASH progression in hepatic Mettl3 knockout mice. Hepatic overexpression of Mettl3 protects against NASH progression by inhibiting the expression of CD36 and CCL2. Mechanistically, METTL3 directly binds to the promoters of the Cd36 and Ccl2 genes and recruits HDAC1/2 to induce deacetylation of H3K9 and H3K27 in their promoters, thus suppressing Cd36 and Ccl2 transcription. Furthermore, METTL3 is translocated from the nucleus to the cytosol in NASH, which is associated with CDK9-mediated phosphorylation of METTL3. Our data reveal a mechanism by which METTL3 negatively regulates hepatic Cd36 and Ccl2 gene transcription via a histone modification pathway for protection against NASH progression.

Citing Articles

Macrophage-derived lncRNAs in cancer: regulators of tumor progression and therapeutic targets.

Suliman M, Saleh R, Chandra M, Rasool K, Jabir M, Jawad S Med Oncol. 2025; 42(4):91.

PMID: 40048034 DOI: 10.1007/s12032-025-02643-2.

Inhibition of CD36 ameliorates mouse spinal cord injury by accelerating microglial lipophagy.

Wang B, Du A, Chen X, Huang T, Al Mamun A, Li P Acta Pharmacol Sin. 2025; .

PMID: 39880928 DOI: 10.1038/s41401-024-01463-w.

Promotion of nonalcoholic steatohepatitis by RNA N-methyladenosine reader IGF2BP2 in mice.

Zhou B, Luo Y, Ji N, Mao F, Xiang L, Bian H Life Metab. 2025; 1(2):161-174.

PMID: 39872354 PMC: 11749640. DOI: 10.1093/lifemeta/loac006.

WTAP regulates postnatal development of brown adipose tissue by stabilizing METTL3 in mice.

Wang Y, Li X, Liu C, Zhou L, Shi L, Zhang Z Life Metab. 2025; 1(3):270-284.

PMID: 39872074 PMC: 11749075. DOI: 10.1093/lifemeta/loac028.

WTAP: a new player in postnatal BAT development.

Sun L Life Metab. 2025; 1(3):201-202.

PMID: 39872070 PMC: 11749253. DOI: 10.1093/lifemeta/loac031.

References

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Diehl A, Day C . Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med. 2017; 377(21):2063-2072. DOI: 10.1056/NEJMra1503519. View

Anstee Q, Reeves H, Kotsiliti E, Govaere O, Heikenwalder M . From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019; 16(7):411-428. DOI: 10.1038/s41575-019-0145-7. View

Verdelho Machado M, Diehl A . Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology. 2016; 150(8):1769-77. PMC: 4887389. DOI: 10.1053/j.gastro.2016.02.066. View

Kazankov K, Jorgensen S, Thomsen K, Moller H, Vilstrup H, George J . The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2018; 16(3):145-159. DOI: 10.1038/s41575-018-0082-x. View

Day C, James O . Steatohepatitis: a tale of two "hits"?. Gastroenterology. 1998; 114(4):842-5. DOI: 10.1016/s0016-5085(98)70599-2. View

Friedman S, Neuschwander-Tetri B, Rinella M, Sanyal A . Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24(7):908-922. PMC: 6553468. DOI: 10.1038/s41591-018-0104-9. View

Donnelly K, Smith C, Schwarzenberg S, Jessurun J, Boldt M, Parks E . Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115(5):1343-51. PMC: 1087172. DOI: 10.1172/JCI23621. View

10.

Schuster S, Cabrera D, Arrese M, Feldstein A . Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018; 15(6):349-364. DOI: 10.1038/s41575-018-0009-6. View

11.

Sanyal A . Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019; 16(6):377-386. DOI: 10.1038/s41575-019-0144-8. View

12.

Miquilena-Colina M, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla M, Fernandez-Bermejo M, Lozano-Rodriguez T . Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011; 60(10):1394-402. DOI: 10.1136/gut.2010.222844. View

13.

Bieghs V, Wouters K, van Gorp P, Gijbels M, de Winther M, Binder C . Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology. 2010; 138(7):2477-86, 2486.e1-3. PMC: 3114629. DOI: 10.1053/j.gastro.2010.02.051. View

14.

Haukeland J, Damas J, Konopski Z, Loberg E, Haaland T, Goverud I . Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44(6):1167-74. DOI: 10.1016/j.jhep.2006.02.011. View

15.

Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E . Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012; 302(11):G1310-21. PMC: 3378163. DOI: 10.1152/ajpgi.00365.2011. View

16.

Baeck C, Wehr A, Karlmark K, Heymann F, Vucur M, Gassler N . Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2011; 61(3):416-26. DOI: 10.1136/gutjnl-2011-300304. View

17.

Lefebvre E, Moyle G, Reshef R, Richman L, Thompson M, Hong F . Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016; 11(6):e0158156. PMC: 4922569. DOI: 10.1371/journal.pone.0158156. View

18.

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L . A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2013; 10(2):93-5. PMC: 3911877. DOI: 10.1038/nchembio.1432. View

19.

Ping X, Sun B, Wang L, Xiao W, Yang X, Wang W . Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014; 24(2):177-89. PMC: 3915904. DOI: 10.1038/cr.2014.3. View

20.

Frye M, Harada B, Behm M, He C . RNA modifications modulate gene expression during development. Science. 2018; 361(6409):1346-1349. PMC: 6436390. DOI: 10.1126/science.aau1646. View